Trial Profile

A randomized, double-blind, placebo-controlled, single ascending dose study of CIN-110 in otherwise healthy subjects with obesity

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CIN 110 (Primary)
Indications Obesity
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

03 Nov 2024 According to a CinFina Pharma media release, data from this study were presented at ObesityWeek 2024.
03 Nov 2024 Interim results presented in a CinFina Pharma Media Release.
23 Oct 2024 According to a CinFina Pharma media release, company will be presenting a late-breaking poster of interim single-ascending dose data for CIN-110 at ObesityWeek 2024, held at the Henry B. Gonzalez Convention Center in San Antonio from November 2nd to 6th.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com